Navigation Links
FDA Clears Test for Bacteria That Can Cause Serious Intestinal Disease
Date:4/8/2011

SILVER SPRING, Md., April 8, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today cleared a test called the Cepheid Xpert C. difficile/Epi assay that is designed to rapidly detect the toxin B gene associated with Clostridium difficile infection (CDI), a cause of diarrhea that can lead to colitis, other serious intestinal conditions and death in severe cases.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Clostridium difficile (C. difficile) bacteria are found in the stool of an infected person. Others can become infected if they touch items or surfaces contaminated with the bacteria or spores and then touch their mouth.

The Cepheid Xpert C. difficile/Epi assay is automated and works on the Cepheid GeneXpert Dx System to detect toxin gene sequences associated with toxigenic C. difficile. The Cepheid GeneXpert Dx System consists of an instrument that houses single-use disposable cartridges, a personal computer, and software that allow a laboratory technician to run tests and view test results quickly.

The test, Cepheid Xpert C. difficile/Epi assay, determines if C. difficile is in a patient's stool and also detects if the C. difficile is the epidemic 027/NAP1/BI strain, which has been associated with a marked increase in the severity and incidence of CDI in North America and Europe over the past decade.

The test is intended for use as an aid in the diagnosis of CDI. The detection of the 027/NAP1/B1 strain is for epidemiological purposes only and should not be used to determine or monitor treatment. Health care facilities should monitor the number of C. difficile infections and, especially if rates at the facility increase, the severity of disease and patient outcomes.

"Health care professionals in the infectious disease community who have seen various out
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
2. FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids
3. FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors
4. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
5. FDA Clears a Test for Ovarian Cancer
6. Private Investment Firm Czura Thornton Today Introduces Clearstone Central Laboratories as the Newest Member of the Czura Thornton Life Science Group
7. U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States
8. FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets
9. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
10. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
11. FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that it ... June 30, 2015, on Thursday, August 6, 2015, after the ... 4:30 p.m. Eastern Time to discuss the financial results and ... Conference Call Details To access the live conference call on ... please dial 877-703-6106 from the United States ...
(Date:7/27/2015)... IRVINE, Calif. , July 27, 2015 ... ELOS ) , a global market leader in ... has received Korean Ministry of Food and Drug Safety ... this regulatory clearance, the Company can fulfill PicoWay orders ... activity in Korea anticipated later in the third quarter ...
(Date:7/27/2015)... YORK , July 27, 2015  Relmada ... novel therapies for the treatment of chronic pain, ... Trial Application (CTA) with Heath Canada ... study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate ... of neuropathic pain. "We are very ...
Breaking Medicine Technology:Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 4Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone 2Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone 3
... NEW YORK, June 3 Delcath Systems, Inc.,(Nasdaq: ... Center of,Bethlehem, PA, part of St. Luke,s Hospital & ... trial for the treatment of,inoperable metastatic melanoma in the ... the isolated, high dose,delivery of the anti-cancer agent melphalan. ...
... Data Presented at ASCO Show 26% Partial Response, 63% Clinical Benefit ... ... Calif., June 3 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... antitumor activity in a Phase 2,trial when administered in combination with ...
Cached Medicine Technology:Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 2Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 2Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 4Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 5Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 6
(Date:7/28/2015)... ... July 28, 2015 , ... PeopleKeys today announced that their ... the EY Entrepreneur of the Year award. The award recognizes the important strides ... the innovative work they have done in incorporating new technology, processes, and procedures ...
(Date:7/28/2015)... ... ... Maryland Brain & Spine has adopted a new name – Maryland Brain, Spine ... techniques, and additional state-of-the art online resources for patients. MBSP is ... and spine conditions. , “Adding the word ‘pain’ may not seem like a ...
(Date:7/28/2015)... ... July 28, 2015 , ... One of the most common ... is plantar fasciitis . Zensah, the Miami-based compression brand, offers a product ... athletic trainer, the Zensah Ankle Support’s primary benefits include helping support the ankle, ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... to offer online RN to BSN cohorts for Geisinger Health System ... partnership provides GHS diploma and associate degree prepared nurses with access to American ...
(Date:7/28/2015)... ... July 28, 2015 , ... Carol McFarland, ... with discussion and demonstration of specific rehabilitation exercises and treatment protocols in the ... surgical process with an extensive interview conducted by Carol with a board certified ...
Breaking Medicine News(10 mins):Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 2Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 2Health News:Maryland Brain & Spine Announces New Specialty, New Name 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 4Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 3Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 4Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 2Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 3Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 4Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 5Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 6
... Researchers at the University of Texas, have shown that use ... cancer.Up to 70 per cent of US women born since ... suggested that use of the hormones in the Pill could ... have failed to reveal a connection. The early Pill users ...
... to day problem among the adolescents. Every day, more than ... young smokers will eventually die from tobacco-related causes.// A new ... are among the driving forces causing young girls to become ... Institute, followed more than 1,500 young girls, beginning at ages ...
... of taking care your medication. Sometimes half a pill does the ... a medication, or be given a double dose of a medicine ... into two or more doses. ,Doctors at the Mayo ... splitting. First, you need to check if your pill is amenable ...
... darkness might prevent retinal damage in diabetes. One of the ... diabetic retinopathy. This results from damage to the retina //- ... which responds to light.In diabetes, the blood supply to the ... rods (the cells responsible for night vision) which have a ...
... a type of ultrasound test may be able to identify ... most common causes of sudden death in young people.The condition, ... different mutations in as many as 10 genes. In HCM, ... pump blood and putting patients at risk of heart failure ...
... at home reduces hospitalisation in those with lung disease. Researchers ... of oxygen on 200 patients with smoker's lungs - where ... in an outpatient clinic, then continued at home. ... proved to be beneficial. The patients had a 40 per ...
Cached Medicine News:Health News:What makes young girls smoke 2Health News:Ultrasound test may detect heart condition early 2
Silicone Elastomer-Coated Latex Foley Catheters 2-Way...
Silicone Foley Catheters 3-Way...
Midstream Catch Kits...
... The BladderScan® BVI 6300 Bladder Monitor ... prescribed by the healthcare provider to ... on an ongoing basis. It is ... accurate results, so the patient can ...
Medicine Products: